Compare HFWA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | IMTX |
|---|---|---|
| Founded | 1927 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1997 | N/A |
| Metric | HFWA | IMTX |
|---|---|---|
| Price | $29.24 | $9.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $30.50 | $19.00 |
| AVG Volume (30 Days) | ★ 463.9K | 387.7K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 58.06 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.85 | N/A |
| Revenue Next Year | $7.83 | $25.91 |
| P/E Ratio | $61.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.32 | $5.05 |
| 52 Week High | $31.25 | $12.41 |
| Indicator | HFWA | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 54.27 |
| Support Level | $28.91 | $9.58 |
| Resistance Level | $29.29 | $10.67 |
| Average True Range (ATR) | 0.69 | 0.52 |
| MACD | -0.15 | 0.11 |
| Stochastic Oscillator | 15.26 | 88.79 |
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.